Roland C Grafstrom
Overview
Explore the profile of Roland C Grafstrom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ceder R, Haig Y, Merne M, Hansson A, Zheng X, Roberg K, et al.
Am J Pathol
. 2011 Dec;
180(2):457-72.
PMID: 22142811
Aberrant contact-inhibited proliferation and differentiation induction couple with tumor severity, albeit with an imprecise association with prognosis. Assessment of contact inhibition and differentiation-promoting culture in this study of normal and...
12.
Willighagen E, Jeliazkova N, Hardy B, Grafstrom R, Spjuth O
BMC Res Notes
. 2011 Nov;
4:487.
PMID: 22075173
Background: Toxicity is a complex phenomenon involving the potential adverse effect on a range of biological functions. Predicting toxicity involves using a combination of experimental data (endpoints) and computational methods...
13.
Farnebo L, Jerhammar F, Ceder R, Grafstrom R, Vainikka L, Thunell L, et al.
J Oral Pathol Med
. 2011 Apr;
40(10):739-46.
PMID: 21481002
Background: Radiotherapy is the main therapy for head and neck squamous cell carcinoma (HNSCC); however, treatment resistance and local recurrence are significant problems, highlighting the need for predictive markers. In...
14.
15.
Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom R, Roberg K
Cancer Biol Ther
. 2010 Oct;
10(12):1244-51.
PMID: 20930522
Radiotherapy remains the backbone of head and neck cancer therapy but response is sometimes impeded by tumor radioresistance. Identifying predictive biomarkers of radiotherapy response is a crucial step towards personalized...
16.
Nilsson C, Roberg K, Grafstrom R, Ollinger K
Head Neck
. 2009 Dec;
32(9):1185-94.
PMID: 20029982
Background: Cisplatin treatment is beneficial for approximately 20% of patients with head and neck squamous cell carcinoma (HNSCC). Tools to predict the clinical outcome and evaluate intrinsic cisplatin sensitivity are,...
17.
Thompson C, Ceder R, Grafstrom R
Toxicol Lett
. 2009 Dec;
193(1):1-3.
PMID: 19963048
Formaldehyde dehydrogenase, formally Class III alcohol dehydrogenase (ADH3), has recently been discovered to partially regulate nitrosothiol homeostasis by catalyzing the reduction of the endogenous nitrosylating agent S-nitrosoglutathione (GSNO). Several studies...
18.
Thompson C, Grafstrom R
Environ Health
. 2009 Nov;
8:53.
PMID: 19939253
Occupational exposure to formaldehyde has been linked to nasopharyngeal carcinoma. To date, mechanistic explanations for this association have primarily focused on formaldehyde-induced cytotoxicity, regenerative hyperplasia and DNA damage. However, recent...
19.
Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al.
Clin Cancer Res
. 2009 Oct;
15(19):6070-8.
PMID: 19789329
Purpose: To identify novel therapeutic opportunities for patients with prostate cancer, we applied high-throughput screening to systematically explore most currently marketed drugs and drug-like molecules for their efficacy against a...
20.
Thompson C, Sonawane B, Grafstrom R
Drug Metab Dispos
. 2009 May;
37(8):1565-71.
PMID: 19460944
Class III alcohol dehydrogenase (ADH3), also termed formaldehyde dehydrogenase or S-nitrosoglutathione reductase, plays a critical role in the enzymatic oxidation of formaldehyde and reduction of nitrosothiols that regulate bronchial tone....